{"protocolSection":{"identificationModule":{"nctId":"NCT02953314","orgStudyIdInfo":{"id":"VX15-661-113"},"secondaryIdInfos":[{"id":"2017-001164-38","type":"EUDRACT_NUMBER"}],"organization":{"fullName":"Vertex Pharmaceuticals Incorporated","class":"INDUSTRY"},"briefTitle":"A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of VX-661/Ivacaftor in Pediatric Subjects With Cystic Fibrosis (CF)","officialTitle":"A Phase 3, Open Label Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of VX-661 in Combination With Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis, Homozygous or Heterozygous for the F508del CFTR Mutation"},"statusModule":{"statusVerifiedDate":"2020-02","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2016-11","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2018-09","type":"ACTUAL"},"completionDateStruct":{"date":"2018-09","type":"ACTUAL"},"studyFirstSubmitDate":"2016-10-18","studyFirstSubmitQcDate":"2016-10-31","studyFirstPostDateStruct":{"date":"2016-11-02","type":"ESTIMATED"},"resultsFirstSubmitDate":"2019-09-30","resultsFirstSubmitQcDate":"2019-11-15","resultsFirstPostDateStruct":{"date":"2019-12-05","type":"ACTUAL"},"lastUpdateSubmitDate":"2020-02-25","lastUpdatePostDateStruct":{"date":"2020-03-04","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Vertex Pharmaceuticals Incorporated","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"This is a Phase 3, 2-part (Part A and Part B), open label, multicenter study evaluating the pharmacokinetic (PK), safety, and tolerability of multiple doses of tezacaftor (TEZ) in combination with ivacaftor (IVA) in subjects 6 through 11 years of age with CF who are homozygous or heterozygous for the F508del- CF transmembrane conductance regulator protein (CFTR) mutation."},"conditionsModule":{"conditions":["Cystic Fibrosis"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"NON_RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":83,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Part A","type":"EXPERIMENTAL","description":"Participants weighing \\<25 kg received TEZ 50 mg once daily/IVA 75 mg q12h orally for 14 days.\n\nParticipants weighing ≥25 kg received TEZ 50 mg once daily/IVA 150 mg q12h orally for 14 days.","interventionNames":["Drug: TEZ","Drug: IVA"]},{"label":"Part B","type":"EXPERIMENTAL","description":"Participants weighing \\<40 kg received TEZ 50 mg/IVA 75 mg as fixed dose combination orally once daily in the morning and IVA 75 mg orally once daily in the evening for 24 weeks.\n\nParticipants weighing ≥40 kg received TEZ 100 mg/IVA 150 mg as fixed dose combination orally once daily in the morning and IVA 150 mg orally once daily in the evening for 24 weeks.","interventionNames":["Drug: TEZ/IVA","Drug: IVA"]}],"interventions":[{"type":"DRUG","name":"TEZ","armGroupLabels":["Part A"],"otherNames":["tezacaftor","VX-661"]},{"type":"DRUG","name":"TEZ/IVA","armGroupLabels":["Part B"],"otherNames":["tezacaftor/ivacaftor","VX-661/VX-770"]},{"type":"DRUG","name":"IVA","armGroupLabels":["Part A","Part B"],"otherNames":["ivacaftor","VX-770"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Part A: Maximum Observed Concentration (Cmax) of TEZ and IVA","timeFrame":"Day 1 and Day 14"},{"measure":"Part A: Area Under the Concentration Versus Time Curve During Dosing Interval (AUCtau) of TEZ and IVA","timeFrame":"Day 1 and Day 14"},{"measure":"Part B: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)","timeFrame":"Day 1 up to Week 28"}],"secondaryOutcomes":[{"measure":"Part A: Cmax of TEZ Metabolites (M1-TEZ, M2-TEZ) and IVA Metabolites (M1-IVA, M6-IVA)","timeFrame":"Day 1 and Day 14"},{"measure":"Part A: AUCtau of TEZ Metabolites (M1-TEZ, M2-TEZ) and IVA Metabolites (M1-IVA, M6-IVA)","timeFrame":"Day 1 and Day 14"},{"measure":"Part A: Number of Participants With AEs and SAEs","timeFrame":"Day 1 up to Day 28"},{"measure":"Part B: Cmax of TEZ, TEZ Metabolites (M1-TEZ, M2-TEZ), IVA, and IVA Metabolites (M1-IVA, M6-IVA)","timeFrame":"Week 16"},{"measure":"Part B: AUCtau of TEZ, TEZ Metabolites (M1-TEZ, M2-TEZ), IVA, and IVA Metabolites (M1-IVA, M6-IVA )","timeFrame":"Week 16"},{"measure":"Part B: Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)","description":"FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.","timeFrame":"From Baseline through Week 24"},{"measure":"Part B: Relative Change in ppFEV1","description":"FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.","timeFrame":"From Baseline through Week 24"},{"measure":"Part B: Absolute Change in Weight","timeFrame":"From Baseline at Week 24"},{"measure":"Part B: Absolute Change in Weight-for-age Z-Score","description":"z-score is a statistical measure to describe whether a mean was above or below the standard. Weight, adjusted for age and sex, was analyzed as weight-for-age z-score. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean. Higher values are indicative of higher weight.","timeFrame":"From Baseline at Week 24"},{"measure":"Part B: Absolute Change in Height","timeFrame":"From Baseline at Week 24"},{"measure":"Part B: Absolute Change in Height-for-age z-Score","description":"z-score is a statistical measure to describe whether a mean was above or below the standard. Height, adjusted for age and sex, was analyzed as height-for-age z-score. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean. Higher values are indicative of higher height.","timeFrame":"From Baseline at Week 24"},{"measure":"Part B: Absolute Change in Body Mass Index (BMI)","description":"BMI was defined as weight in kg divided by height in square meter (m\\^2).","timeFrame":"From Baseline at Week 24"},{"measure":"Part B: Absolute Change in BMI-for-age z-Score","description":"BMI was defined as weight in kg divided by height in m\\^2. z-score is a statistical measure to describe whether a mean was above or below the standard. BMI, adjusted for age and sex, was analyzed as BMI-for-age z-score. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean. Higher values are indicative of higher BMI.","timeFrame":"From Baseline at Week 24"},{"measure":"Part B: Absolute Change in Sweat Chloride","description":"Sweat samples were collected using an approved collection device.","timeFrame":"From Baseline through Week 4"},{"measure":"Part B: Absolute Change in Sweat Chloride","description":"Sweat samples were collected using an approved collection device.","timeFrame":"From Baseline through Week 24"},{"measure":"Part B: Absolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score","description":"The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.","timeFrame":"From Baseline through Week 24"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects who weigh ≥15 kg without shoes at the Screening Visit.\n* All genotypes as specified by the study protocol are eligible in Part A.\n* The following genotypes are eligible in Part B:\n\n  * homozygous for the F508del CFTR mutation\n  * heterozygous for the F508del CFTR mutation and with a second allele with a CFTR mutation predicted to have residual function.\n  * heterozygous for the F508del CFTR mutation and with a second CFTR allele with a gating defect that is clinically demonstrated to be ivacaftor responsive\n* Subjects with a confirmed diagnosis of CF defined as a sweat chloride value ≥60 mmol/L or chronic sinopulmonary and/or gastrointestinal disease consistent with a diagnosis of CF. Subjects who are homozygous for the F508del-CFTR mutation must have a sweat chloride value ≥60 mmol/L.\n* Subjects with ppFEV1 of ≥40 percentage points at the Screening Visit\n* Subjects with stable CF disease as deemed by the investigator at the Screening Visit.\n* Subjects who are willing to remain on their stable CF medication regimen through Day 14 (Part A) or through Week 24 (Part B) or, if applicable, through the Safety Follow up Visit.\n* Subjects who are able to swallow tablets.\n* Female subjects of childbearing potential must have a negative serum pregnancy test at the Screening Visit and a negative urine pregnancy test at the Day 1 Visit before receiving the first dose of study drug.\n* Subjects of childbearing potential who are sexually active must meet the contraception requirements\n\nExclusion Criteria:\n\n* History of any comorbidity reviewed at the Screening Visit that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study drug to the subject.\n* Any clinically significant laboratory abnormalities at the Screening Visit that would interfere with the study assessments or pose an undue risk for the subject.\n* An acute upper or lower respiratory infection, pulmonary exacerbation, or changes in therapy for pulmonary disease within 28 days before Day 1\n* Colonization with organisms associated with a more rapid decline in pulmonary status.\n* A standard 12 lead ECG demonstrating QTc \\>450 msec at the Screening Visit.\n* History of solid organ or hematological transplantation at the Screening Visit.\n* Ongoing or prior participation in an investigational drug study or use of commercially available CFTR modulator (except physician-prescribed Kalydeco for approved indications) within 30 days of screening.\n* Use of restricted medication or food within a specified duration before the Screening Visit or first dose of study drug and/or unwillingness to maintain the restrictions.\n* History or evidence of cataract, lens opacity, Y-suture, or lamellar rings determined to be clinically significant by the ophthalmologist during the ophthalmologic examination at the Screening Visit.\n* Pregnant and nursing females.","healthyVolunteers":false,"sex":"ALL","minimumAge":"6 Years","maximumAge":"11 Years","stdAges":["CHILD"]},"contactsLocationsModule":{"locations":[{"city":"Birmingham","state":"Alabama","country":"United States","geoPoint":{"lat":33.52066,"lon":-86.80249}},{"city":"Anchorage","state":"Alaska","country":"United States","geoPoint":{"lat":61.21806,"lon":-149.90028}},{"city":"Little Rock","state":"Arkansas","country":"United States","geoPoint":{"lat":34.74648,"lon":-92.28959}},{"city":"Los Angeles","state":"California","country":"United States","geoPoint":{"lat":34.05223,"lon":-118.24368}},{"city":"Palo Alto","state":"California","country":"United States","geoPoint":{"lat":37.44188,"lon":-122.14302}},{"city":"Aurora","state":"Colorado","country":"United States","geoPoint":{"lat":39.72943,"lon":-104.83192}},{"city":"Wilmington","state":"Delaware","country":"United States","geoPoint":{"lat":39.74595,"lon":-75.54659}},{"city":"Orlando","state":"Florida","country":"United States","geoPoint":{"lat":28.53834,"lon":-81.37924}},{"city":"Saint Petersburg","state":"Florida","country":"United States","geoPoint":{"lat":27.77086,"lon":-82.67927}},{"city":"Atlanta","state":"Georgia","country":"United States","geoPoint":{"lat":33.749,"lon":-84.38798}},{"city":"Boise","state":"Idaho","country":"United States","geoPoint":{"lat":43.6135,"lon":-116.20345}},{"city":"Indianapolis","state":"Indiana","country":"United States","geoPoint":{"lat":39.76838,"lon":-86.15804}},{"city":"Boston","state":"Massachusetts","country":"United States","geoPoint":{"lat":42.35843,"lon":-71.05977}},{"city":"Minneapolis","state":"Minnesota","country":"United States","geoPoint":{"lat":44.97997,"lon":-93.26384}},{"city":"Kansas City","state":"Missouri","country":"United States","geoPoint":{"lat":39.09973,"lon":-94.57857}},{"city":"Manchester","state":"New Hampshire","country":"United States","geoPoint":{"lat":42.99564,"lon":-71.45479}},{"city":"Buffalo","state":"New York","country":"United States","geoPoint":{"lat":42.88645,"lon":-78.87837}},{"city":"New York","state":"New York","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"city":"Syracuse","state":"New York","country":"United States","geoPoint":{"lat":43.04812,"lon":-76.14742}},{"city":"Winston-Salem","state":"North Carolina","country":"United States","geoPoint":{"lat":36.09986,"lon":-80.24422}},{"city":"Cleveland","state":"Ohio","country":"United States","geoPoint":{"lat":41.4995,"lon":-81.69541}},{"city":"Pittsburgh","state":"Pennsylvania","country":"United States","geoPoint":{"lat":40.44062,"lon":-79.99589}},{"city":"Charleston","state":"South Carolina","country":"United States","geoPoint":{"lat":32.77657,"lon":-79.93092}},{"city":"Sioux Falls","state":"South Dakota","country":"United States","geoPoint":{"lat":43.54997,"lon":-96.70033}},{"city":"Austin","state":"Texas","country":"United States","geoPoint":{"lat":30.26715,"lon":-97.74306}},{"city":"Fort Worth","state":"Texas","country":"United States","geoPoint":{"lat":32.72541,"lon":-97.32085}},{"city":"Houston","state":"Texas","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}},{"city":"Norfolk","state":"Virginia","country":"United States","geoPoint":{"lat":36.84681,"lon":-76.28522}},{"city":"Seattle","state":"Washington","country":"United States","geoPoint":{"lat":47.60621,"lon":-122.33207}},{"city":"Milwaukee","state":"Wisconsin","country":"United States","geoPoint":{"lat":43.0389,"lon":-87.90647}},{"city":"Vancouver","state":"British Columbia","country":"Canada","geoPoint":{"lat":49.24966,"lon":-123.11934}},{"city":"Toronto","state":"Ontario","country":"Canada","geoPoint":{"lat":43.70011,"lon":-79.4163}},{"city":"Montréal","state":"Quebec","country":"Canada","geoPoint":{"lat":45.50884,"lon":-73.58781}}]},"referencesModule":{"references":[{"pmid":"31253540","type":"DERIVED","citation":"Walker S, Flume P, McNamara J, Solomon M, Chilvers M, Chmiel J, Harris RS, Haseltine E, Stiles D, Li C, Ahluwalia N, Zhou H, Owen CA, Sawicki G; VX15-661-113 Investigator Group. A phase 3 study of tezacaftor in combination with ivacaftor in children aged 6 through 11 years with cystic fibrosis. J Cyst Fibros. 2019 Sep;18(5):708-713. doi: 10.1016/j.jcf.2019.06.009. Epub 2019 Jun 26."}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"This study consisted of 2-parts (Part A and B). The planned primary analysis was designed to assess overall treatment arm \"TEZ/IVA\", irrespective of weight-based dosing regimen. The aim of weight based dosing is to achieve similar exposures in children of different weights, thus analysis is presented for the single treatment arm \"TEZ/IVA\".","groups":[{"id":"FG000","title":"Part A","description":"Participants weighing \\<25 kg received TEZ 50 mg/IVA 75 mg for 14 days.\n\nParticipants weighing ≥25 kg received TEZ 50 mg/IVA 150 mg for 14 days."},{"id":"FG001","title":"Part B","description":"Participants weighing \\<40 kg received TEZ 50 mg/IVA 75 mg as fixed dose combination in the morning and IVA 75 mg orally in the evening for 24 weeks.\n\nParticipants weighing ≥40 kg received TEZ 100 mg/IVA 150 mg as fixed dose combination in the morning and IVA 150 mg in the evening for 24 weeks."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"13"},{"groupId":"FG001","numSubjects":"70"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"13"},{"groupId":"FG001","numSubjects":"67"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"3"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}]},{"type":"Withdrawal of consent (not due to AE)","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"2"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Part A","description":"Participants weighing \\<25 kg received TEZ 50 mg/IVA 75 mg for 14 days. Participants weighing ≥25 kg received TEZ 50 mg/IVA 150 mg for 14 days."},{"id":"BG001","title":"Part B","description":"Participants weighing \\<40 kg received TEZ 50 mg/IVA 75 mg as fixed dose combination in the morning and IVA 75 mg in the evening for 24 weeks.\n\nParticipants weighing ≥40 kg received TEZ 100 mg/IVA 150 mg as fixed dose combination in the morning and IVA 150 mg in the evening for 24 weeks."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"13"},{"groupId":"BG001","value":"70"},{"groupId":"BG002","value":"83"}]}],"measures":[{"title":"Age, Categorical","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"<=18 years","measurements":[{"groupId":"BG000","value":"13"},{"groupId":"BG001","value":"70"},{"groupId":"BG002","value":"83"}]},{"title":"Between 18 and 65 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":">=65 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"34"},{"groupId":"BG002","value":"41"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"36"},{"groupId":"BG002","value":"42"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"3"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"13"},{"groupId":"BG001","value":"67"},{"groupId":"BG002","value":"80"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"12"},{"groupId":"BG001","value":"68"},{"groupId":"BG002","value":"80"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Part A: Maximum Observed Concentration (Cmax) of TEZ and IVA","populationDescription":"Pharmacokinetic (PK) set included participants who received at least 1 dose of study drug and for whom the primary PK data were considered to be sufficient and interpretable. Here \"Number Analyzed\" signifies those participants who were evaluable for this outcome measure at specified time points.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"nanogram per milliliter (ng/mL)","timeFrame":"Day 1 and Day 14","groups":[{"id":"OG000","title":"Part A","description":"Participants weighing \\<25 kg received TEZ 50 mg/IVA 75 mg for 14 days. Participants weighing ≥25 kg received TEZ 50 mg/IVA 150 mg for 14 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"classes":[{"title":"Day 1: TEZ (<25 Kg)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6630","spread":"10.3"}]}]},{"title":"Day 1: TEZ (≥25 Kg)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4310","spread":"42.6"}]}]},{"title":"Day 14: TEZ (<25 Kg)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6300","spread":"10.3"}]}]},{"title":"Day 14: TEZ (≥25 Kg)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5340","spread":"49.0"}]}]},{"title":"Day 1: IVA (<25 Kg)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"656"}]}]},{"title":"Day 1: IVA (≥25 Kg)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1010","spread":"64.3"}]}]},{"title":"Day 14: IVA (<25 Kg)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"578","spread":"60.4"}]}]},{"title":"Day 14: IVA (≥25 Kg)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1490","spread":"105"}]}]}]},{"type":"PRIMARY","title":"Part A: Area Under the Concentration Versus Time Curve During Dosing Interval (AUCtau) of TEZ and IVA","populationDescription":"PK set. Here \"Number Analyzed\" signifies those participants who were evaluable for this outcome measure at specified time points.\"Number Analyzed=0\" signified no subjects were evaluated for the specified parameter at that time point.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"hour*nanogram per milliliter (hr*ng/mL)","timeFrame":"Day 1 and Day 14","groups":[{"id":"OG000","title":"Part A","description":"Participants weighing \\<25 kg received TEZ 50 mg/IVA 75 mg for 14 days. Participants weighing ≥25 kg received TEZ 50 mg/IVA 150 mg for 14 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"classes":[{"title":"Day 1: TEZ (<25 Kg)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"54300","spread":"16.2"}]}]},{"title":"Day 1: TEZ (≥25 Kg)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"41600","spread":"36.2"}]}]},{"title":"Day 14: TEZ (<25 Kg)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"66500","spread":"30.5"}]}]},{"title":"Day 14: TEZ (≥25 Kg)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"71600","spread":"61.1"}]}]},{"title":"Day 1: IVA (<25 Kg)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"}]}]},{"title":"Day 1: IVA (≥25 Kg)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"}]}]},{"title":"Day 14: IVA (<25 Kg)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5050","spread":"49.1"}]}]},{"title":"Day 14: IVA (≥25 Kg)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"12400","spread":"118"}]}]}]},{"type":"PRIMARY","title":"Part B: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)","populationDescription":"Safety set: included all participants who received at least 1 dose of study drug. The planned analysis was designed to assess overall treatment arm, irrespective of weight-based dosing regimen. The aim of weight based dosing is to achieve similar exposures in children of different weights, thus analysis is presented for the single treatment arm.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Day 1 up to Week 28","groups":[{"id":"OG000","title":"Part B","description":"Participants weighing \\<40 kg received TEZ 50 mg/IVA 75 mg as fixed dose combination in the morning and IVA 75 mg in the evening for 24 weeks.\n\nParticipants weighing ≥40 kg received TEZ 100 mg/IVA 150 mg as fixed dose combination in the morning and IVA 150 mg in the evening for 24 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"70"}]}],"classes":[{"title":"Participants with AEs","categories":[{"measurements":[{"groupId":"OG000","value":"65"}]}]},{"title":"Participants with SAEs","categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}]}]},{"type":"SECONDARY","title":"Part A: Cmax of TEZ Metabolites (M1-TEZ, M2-TEZ) and IVA Metabolites (M1-IVA, M6-IVA)","populationDescription":"PK set. Here \"Number Analyzed\" signifies those participants who were evaluable for this outcome measure at specified time points.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"ng/mL","timeFrame":"Day 1 and Day 14","groups":[{"id":"OG000","title":"Part A","description":"Participants weighing \\<25 kg received TEZ 50 mg/IVA 75 mg for 14 days. Participants weighing ≥25 kg received TEZ 50 mg/IVA 150 mg for 14 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"classes":[{"title":"Day 1: M1-TEZ (<25 kg)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1720","spread":"3.29"}]}]},{"title":"Day 1: M1-TEZ (≥25 kg)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1530","spread":"22.0"}]}]},{"title":"Day 14: M1-TEZ (<25 kg)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8360","spread":"22"}]}]},{"title":"Day 14: M1-TEZ (≥25 kg)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5930","spread":"19.9"}]}]},{"title":"Day 1: M2-TEZ (<25 kg)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1130","spread":"4.36"}]}]},{"title":"Day 1: M2-TEZ (≥25 kg)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"922","spread":"25.8"}]}]},{"title":"Day 14: M2-TEZ (<25 kg)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6180","spread":"27.2"}]}]},{"title":"Day 14: M2-TEZ (≥25 kg)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5350","spread":"27.2"}]}]},{"title":"Day 1: M1-IVA (<25 kg)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2320"}]}]},{"title":"Day 1: M1-IVA (≥25 kg)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2430","spread":"57.1"}]}]},{"title":"Day 14: M1-IVA (<25 kg)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1460","spread":"34.6"}]}]},{"title":"Day 14: M1-IVA (≥25 kg)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3420","spread":"72.7"}]}]},{"title":"Day 1: M6-IVA (<25 kg)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"849"}]}]},{"title":"Day 1: M6-IVA (≥25 kg)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1070","spread":"55.7"}]}]},{"title":"Day 14: M6-IVA (<25 kg)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1090","spread":"31.4"}]}]},{"title":"Day 14: M6-IVA (≥25 kg)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2720","spread":"59.2"}]}]}]},{"type":"SECONDARY","title":"Part A: AUCtau of TEZ Metabolites (M1-TEZ, M2-TEZ) and IVA Metabolites (M1-IVA, M6-IVA)","populationDescription":"PK set. Here \"Number Analyzed\" signifies those participants who were evaluable for this outcome measure at specified time points. \"Number Analyzed=0\" signified no subjects were evaluated for the specified parameter at that time point.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"hr*ng/mL","timeFrame":"Day 1 and Day 14","groups":[{"id":"OG000","title":"Part A","description":"Participants weighing \\<25 kg received TEZ 50 mg/IVA 75 mg for 14 days. Participants weighing ≥25 kg received TEZ 50 mg/IVA 150 mg for 14 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"classes":[{"title":"Day 1: M1-TEZ (<25 kg)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"36500","spread":"5.80"}]}]},{"title":"Day 1: M1-TEZ (≥25 kg)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"27400","spread":"26.3"}]}]},{"title":"Day 14: M1-TEZ (<25 kg)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"160000","spread":"15.5"}]}]},{"title":"Day 14: M1-TEZ (≥25 kg)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"121000","spread":"17.1"}]}]},{"title":"Day 1: M2-TEZ (<25 kg)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"14200","spread":"12.3"}]}]},{"title":"Day 1: M2-TEZ (≥25 kg)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"11100","spread":"25.9"}]}]},{"title":"Day 14: M2-TEZ (<25 kg)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"137000","spread":"32.7"}]}]},{"title":"Day 14: M2-TEZ (≥25 kg)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"119000","spread":"27.7"}]}]},{"title":"Day 1: M1-IVA (<25 kg)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"}]}]},{"title":"Day 1: M1-IVA (≥25 kg)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"}]}]},{"title":"Day 14: M1-IVA (<25 kg)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"13700","spread":"52.1"}]}]},{"title":"Day 14: M1-IVA (≥25 kg)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"30300","spread":"81.1"}]}]},{"title":"Day 1: M6-IVA (<25 kg)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"}]}]},{"title":"Day 1: M6-IVA (≥25 kg)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"}]}]},{"title":"Day 14: M6-IVA (<25 kg)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"10200","spread":"58.5"}]}]},{"title":"Day 14: M6-IVA (≥25 kg)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"26000","spread":"70.6"}]}]}]},{"type":"SECONDARY","title":"Part A: Number of Participants With AEs and SAEs","populationDescription":"Safety set: included all participants who received at least 1 dose of study drug. The planned analysis was designed to assess overall treatment arm, irrespective of weight-based dosing regimen. The aim of weight based dosing is to achieve similar exposures in children of different weights, thus analysis is presented for the single treatment arm.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Day 1 up to Day 28","groups":[{"id":"OG000","title":"Part A","description":"Participants weighing \\<25 kg received TEZ 50 mg/IVA 75 mg for 14 days. Participants weighing ≥25 kg received TEZ 50 mg/IVA 150 mg for 14 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"classes":[{"title":"Participants with AEs","categories":[{"measurements":[{"groupId":"OG000","value":"12"}]}]},{"title":"Participants with SAEs","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}]},{"type":"SECONDARY","title":"Part B: Cmax of TEZ, TEZ Metabolites (M1-TEZ, M2-TEZ), IVA, and IVA Metabolites (M1-IVA, M6-IVA)","populationDescription":"PK set. Here \"Overall Number of Participants Analyzed\" signifies those participants who were evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"ng/mL","timeFrame":"Week 16","groups":[{"id":"OG000","title":"Part B","description":"Participants weighing \\<40 kg received TEZ 50 mg/IVA 75 mg as fixed dose combination in the morning and IVA 75 mg in the evening for 24 weeks.\n\nParticipants weighing ≥40 kg received TEZ 100 mg/IVA 150 mg as fixed dose combination in the morning and IVA 150 mg in the evening for 24 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"69"}]}],"classes":[{"title":"TEZ (<40 kg)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"62"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4800","spread":"33.7"}]}]},{"title":"TEZ (≥40 kg)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5870","spread":"46.5"}]}]},{"title":"M1-TEZ (<40 kg)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"62"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5310","spread":"36.0"}]}]},{"title":"M1-TEZ (≥40 kg)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5440","spread":"61.5"}]}]},{"title":"M2-TEZ (<40 kg)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"62"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4170","spread":"47.4"}]}]},{"title":"M2-TEZ (≥40 kg)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5210","spread":"55.0"}]}]},{"title":"IVA (<40 kg)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"62"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"725","spread":"56.9"}]}]},{"title":"IVA (≥40 kg)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"886","spread":"58.7"}]}]},{"title":"M1-IVA (<40 kg)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"62"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1560","spread":"54.8"}]}]},{"title":"M1-IVA (≥40 kg)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1870","spread":"50.2"}]}]},{"title":"M6-IVA (<40 kg)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"62"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"870","spread":"69.2"}]}]},{"title":"M6-IVA (≥40 kg)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1120","spread":"29.5"}]}]}]},{"type":"SECONDARY","title":"Part B: AUCtau of TEZ, TEZ Metabolites (M1-TEZ, M2-TEZ), IVA, and IVA Metabolites (M1-IVA, M6-IVA )","populationDescription":"PK set. Here \"Number Analyzed\" signifies those participants who were evaluable for this outcome measure at specified time points.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"hr*ng/mL","timeFrame":"Week 16","groups":[{"id":"OG000","title":"Part B","description":"Participants weighing \\<40 kg received TEZ 50 mg/IVA 75 mg as fixed dose combination in the morning and IVA 75 mg in the evening for 24 weeks.\n\nParticipants weighing ≥40 kg received TEZ 100 mg/IVA 150 mg as fixed dose combination in the morning and IVA 150 mg in the evening for 24 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"69"}]}],"classes":[{"title":"TEZ (<40 kg)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"61"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"50300","spread":"36.3"}]}]},{"title":"TEZ (≥40 kg)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"60900","spread":"50.6"}]}]},{"title":"M1-TEZ (<40 kg)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"61"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"104000","spread":"44.2"}]}]},{"title":"M1-TEZ (≥40 kg)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100000","spread":"87.2"}]}]},{"title":"M2-TEZ (<40 kg)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"61"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"88400","spread":"57.0"}]}]},{"title":"M2-TEZ (≥40 kg)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"93600","spread":"46.5"}]}]},{"title":"IVA (<40 kg)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"59"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5330","spread":"62.2"}]}]},{"title":"IVA (≥40 kg)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7410","spread":"53.8"}]}]},{"title":"M1-IVA (<40 kg)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"59"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"12700","spread":"55.9"}]}]},{"title":"M1-IVA (≥40 kg)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"17200","spread":"40.4"}]}]},{"title":"M6-IVA (<40 kg)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"59"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8140","spread":"70.2"}]}]},{"title":"M6-IVA (≥40 kg)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"11100","spread":"39.4"}]}]}]},{"type":"SECONDARY","title":"Part B: Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)","description":"FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.","populationDescription":"FAS: participants who carry the intended CFTR mutations and received at least 1 dose of study drug. The aim of weight based dosing is to achieve similar exposures in children of different weights, thus the planned analysis is presented for the single treatment arm irrespective of weight-based dosing regimen.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage points","timeFrame":"From Baseline through Week 24","groups":[{"id":"OG000","title":"Part B","description":"Participants weighing \\<40 kg received TEZ 50 mg/IVA 75 mg as fixed dose combination in the morning and IVA 75 mg in the evening for 24 weeks.\n\nParticipants weighing ≥40 kg received TEZ 100 mg/IVA 150 mg as fixed dose combination in the morning and IVA 150 mg in the evening for 24 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"70"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","lowerLimit":"-0.6","upperLimit":"2.3"}]}]}]},{"type":"SECONDARY","title":"Part B: Relative Change in ppFEV1","description":"FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.","populationDescription":"FAS: participants who carry the intended CFTR mutations and received at least 1 dose of study drug. The aim of weight based dosing is to achieve similar exposures in children of different weights, thus the planned analysis is presented for the single treatment arm irrespective of weight-based dosing regimen.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"percent change","timeFrame":"From Baseline through Week 24","groups":[{"id":"OG000","title":"Part B","description":"Participants weighing \\<40 kg received TEZ 50 mg/IVA 75 mg as fixed dose combination in the morning and IVA 75 mg in the evening for 24 weeks.\n\nParticipants weighing ≥40 kg received TEZ 100 mg/IVA 150 mg as fixed dose combination in the morning and IVA 150 mg in the evening for 24 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"70"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","lowerLimit":"-0.4","upperLimit":"3.1"}]}]}]},{"type":"SECONDARY","title":"Part B: Absolute Change in Weight","populationDescription":"FAS: participants who carry the intended CFTR mutations and received at least 1 dose of study drug. The aim of weight based dosing is to achieve similar exposures in children of different weights, thus the planned analysis is presented for the single treatment arm irrespective of weight-based dosing regimen.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"kg","timeFrame":"From Baseline at Week 24","groups":[{"id":"OG000","title":"Part B","description":"Participants weighing \\<40 kg received TEZ 50 mg/IVA 75 mg as fixed dose combination in the morning and IVA 75 mg in the evening for 24 weeks.\n\nParticipants weighing ≥40 kg received TEZ 100 mg/IVA 150 mg as fixed dose combination in the morning and IVA 150 mg in the evening for 24 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"70"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.7","lowerLimit":"1.3","upperLimit":"2.0"}]}]}]},{"type":"SECONDARY","title":"Part B: Absolute Change in Weight-for-age Z-Score","description":"z-score is a statistical measure to describe whether a mean was above or below the standard. Weight, adjusted for age and sex, was analyzed as weight-for-age z-score. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean. Higher values are indicative of higher weight.","populationDescription":"FAS: participants who carry the intended CFTR mutations and received at least 1 dose of study drug. The aim of weight based dosing is to achieve similar exposures in children of different weights, thus the planned analysis is presented for the single treatment arm irrespective of weight-based dosing regimen.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"z-score","timeFrame":"From Baseline at Week 24","groups":[{"id":"OG000","title":"Part B","description":"Participants weighing \\<40 kg received TEZ 50 mg/IVA 75 mg as fixed dose combination in the morning and IVA 75 mg in the evening for 24 weeks.\n\nParticipants weighing ≥40 kg received TEZ 100 mg/IVA 150 mg as fixed dose combination in the morning and IVA 150 mg in the evening for 24 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"70"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","lowerLimit":"-0.05","upperLimit":"0.05"}]}]}]},{"type":"SECONDARY","title":"Part B: Absolute Change in Height","populationDescription":"FAS: participants who carry the intended CFTR mutations and received at least 1 dose of study drug. The aim of weight based dosing is to achieve similar exposures in children of different weights, thus the planned analysis is presented for the single treatment arm irrespective of weight-based dosing regimen.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"centimeter (cm)","timeFrame":"From Baseline at Week 24","groups":[{"id":"OG000","title":"Part B","description":"Participants weighing \\<40 kg received TEZ 50 mg/IVA 75 mg as fixed dose combination in the morning and IVA 75 mg in the evening for 24 weeks.\n\nParticipants weighing ≥40 kg received TEZ 100 mg/IVA 150 mg as fixed dose combination in the morning and IVA 150 mg in the evening for 24 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"70"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.7","lowerLimit":"2.4","upperLimit":"2.9"}]}]}]},{"type":"SECONDARY","title":"Part B: Absolute Change in Height-for-age z-Score","description":"z-score is a statistical measure to describe whether a mean was above or below the standard. Height, adjusted for age and sex, was analyzed as height-for-age z-score. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean. Higher values are indicative of higher height.","populationDescription":"FAS: participants who carry the intended CFTR mutations and received at least 1 dose of study drug. The aim of weight based dosing is to achieve similar exposures in children of different weights, thus the planned analysis is presented for the single treatment arm irrespective of weight-based dosing regimen.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"z-score","timeFrame":"From Baseline at Week 24","groups":[{"id":"OG000","title":"Part B","description":"Participants weighing \\<40 kg received TEZ 50 mg/IVA 75 mg as fixed dose combination in the morning and IVA 75 mg in the evening for 24 weeks.\n\nParticipants weighing ≥40 kg received TEZ 100 mg/IVA 150 mg as fixed dose combination in the morning and IVA 150 mg in the evening for 24 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"70"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","lowerLimit":"-0.05","upperLimit":"0.05"}]}]}]},{"type":"SECONDARY","title":"Part B: Absolute Change in Body Mass Index (BMI)","description":"BMI was defined as weight in kg divided by height in square meter (m\\^2).","populationDescription":"FAS: participants who carry the intended CFTR mutations and received at least 1 dose of study drug. The aim of weight based dosing is to achieve similar exposures in children of different weights, thus the planned analysis is presented for the single treatment arm irrespective of weight-based dosing regimen.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"kg/m^2","timeFrame":"From Baseline at Week 24","groups":[{"id":"OG000","title":"Part B","description":"Participants weighing \\<40 kg received TEZ 50 mg/IVA 75 mg as fixed dose combination in the morning and IVA 75 mg in the evening for 24 weeks.\n\nParticipants weighing ≥40 kg received TEZ 100 mg/IVA 150 mg as fixed dose combination in the morning and IVA 150 mg in the evening for 24 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"70"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.23","lowerLimit":"0.06","upperLimit":"0.40"}]}]}]},{"type":"SECONDARY","title":"Part B: Absolute Change in BMI-for-age z-Score","description":"BMI was defined as weight in kg divided by height in m\\^2. z-score is a statistical measure to describe whether a mean was above or below the standard. BMI, adjusted for age and sex, was analyzed as BMI-for-age z-score. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean. Higher values are indicative of higher BMI.","populationDescription":"FAS: participants who carry the intended CFTR mutations and received at least 1 dose of study drug. The aim of weight based dosing is to achieve similar exposures in children of different weights, thus the planned analysis is presented for the single treatment arm irrespective of weight-based dosing regimen.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"z-score","timeFrame":"From Baseline at Week 24","groups":[{"id":"OG000","title":"Part B","description":"Participants weighing \\<40 kg received TEZ 50 mg/IVA 75 mg as fixed dose combination in the morning and IVA 75 mg in the evening for 24 weeks.\n\nParticipants weighing ≥40 kg received TEZ 100 mg/IVA 150 mg as fixed dose combination in the morning and IVA 150 mg in the evening for 24 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"70"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.03","lowerLimit":"-0.10","upperLimit":"0.04"}]}]}]},{"type":"SECONDARY","title":"Part B: Absolute Change in Sweat Chloride","description":"Sweat samples were collected using an approved collection device.","populationDescription":"FAS: participants who carry the intended CFTR mutations and received at least 1 dose of study drug. The aim of weight based dosing is to achieve similar exposures in children of different weights, thus the planned analysis is presented for the single treatment arm irrespective of weight-based dosing regimen.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"millimole per liter (mmol/L)","timeFrame":"From Baseline through Week 4","groups":[{"id":"OG000","title":"Part B","description":"Participants weighing \\<40 kg received TEZ 50 mg/IVA 75 mg as fixed dose combination in the morning and IVA 75 mg in the evening for 24 weeks.\n\nParticipants weighing ≥40 kg received TEZ 100 mg/IVA 150 mg as fixed dose combination in the morning and IVA 150 mg in the evening for 24 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"70"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-13.0","lowerLimit":"-16.2","upperLimit":"-9.9"}]}]}]},{"type":"SECONDARY","title":"Part B: Absolute Change in Sweat Chloride","description":"Sweat samples were collected using an approved collection device.","populationDescription":"FAS: participants who carry the intended CFTR mutations and received at least 1 dose of study drug. The aim of weight based dosing is to achieve similar exposures in children of different weights, thus the planned analysis is presented for the single treatment arm irrespective of weight-based dosing regimen.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"mmol/L","timeFrame":"From Baseline through Week 24","groups":[{"id":"OG000","title":"Part B","description":"Participants weighing \\<40 kg received TEZ 50 mg/IVA 75 mg as fixed dose combination in the morning and IVA 75 mg in the evening for 24 weeks.\n\nParticipants weighing ≥40 kg received TEZ 100 mg/IVA 150 mg as fixed dose combination in the morning and IVA 150 mg in the evening for 24 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"70"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-14.5","lowerLimit":"-17.4","upperLimit":"-11.6"}]}]}]},{"type":"SECONDARY","title":"Part B: Absolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score","description":"The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.","populationDescription":"FAS: participants who carry the intended CFTR mutations and received at least 1 dose of study drug. The aim of weight based dosing is to achieve similar exposures in children of different weights, thus the planned analysis is presented for the single treatment arm irrespective of weight-based dosing regimen.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"units on a scale","timeFrame":"From Baseline through Week 24","groups":[{"id":"OG000","title":"Part B","description":"Participants weighing \\<40 kg received TEZ 50 mg/IVA 75 mg as fixed dose combination in the morning and IVA 75 mg in the evening for 24 weeks.\n\nParticipants weighing ≥40 kg received TEZ 100 mg/IVA 150 mg as fixed dose combination in the morning and IVA 150 mg in the evening for 24 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"70"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.4","lowerLimit":"1.4","upperLimit":"5.5"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Part A: Day 1 up to Day 28; Part B: Day 1 up to Week 28","description":"Safety set: included all participants who received at least 1 dose of study drug. The planned analysis was designed to assess overall treatment arm, irrespective of weight-based dosing regimen. The aim of weight based dosing is to achieve similar exposures in children of different weights, thus analysis is presented for the single treatment arm for Part A and Part B.","eventGroups":[{"id":"EG000","title":"Part A","description":"Participants weighing \\<25 kg received TEZ 50 mg/IVA 75 mg for 14 days. Participants weighing ≥25 kg received TEZ 50 mg/IVA 150 mg for 14 days.","deathsNumAffected":0,"deathsNumAtRisk":13,"seriousNumAffected":0,"seriousNumAtRisk":13,"otherNumAffected":12,"otherNumAtRisk":13},{"id":"EG001","title":"Part B","description":"Participants weighing \\<40 kg received TEZ 50 mg/IVA 75 mg as fixed dose combination in the morning and IVA 75 mg orally in the evening for 24 weeks.\n\nParticipants weighing ≥40 kg received TEZ 100 mg/IVA 150 mg as fixed dose combination in the morning and IVA 150 mg in the evening for 24 weeks.","deathsNumAffected":0,"deathsNumAtRisk":70,"seriousNumAffected":6,"seriousNumAtRisk":70,"otherNumAffected":62,"otherNumAtRisk":70}],"seriousEvents":[{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":13},{"groupId":"EG001","numAffected":1,"numAtRisk":70}]},{"term":"Breath odour","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":13},{"groupId":"EG001","numAffected":1,"numAtRisk":70}]},{"term":"Infective pulmonary exacerbation of cystic fibrosis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":13},{"groupId":"EG001","numAffected":2,"numAtRisk":70}]},{"term":"Sinusitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":13},{"groupId":"EG001","numAffected":1,"numAtRisk":70}]},{"term":"Failure to thrive","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":13},{"groupId":"EG001","numAffected":1,"numAtRisk":70}]},{"term":"Snoring","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":13},{"groupId":"EG001","numAffected":1,"numAtRisk":70}]}],"otherEvents":[{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":13},{"groupId":"EG001","numAffected":10,"numAtRisk":70}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":13},{"groupId":"EG001","numAffected":5,"numAtRisk":70}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":13},{"groupId":"EG001","numAffected":7,"numAtRisk":70}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13},{"groupId":"EG001","numAffected":2,"numAtRisk":70}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13},{"groupId":"EG001","numAffected":6,"numAtRisk":70}]},{"term":"Infective pulmonary exacerbation of cystic fibrosis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":13},{"groupId":"EG001","numAffected":15,"numAtRisk":70}]},{"term":"Influenza","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":13},{"groupId":"EG001","numAffected":5,"numAtRisk":70}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":13},{"groupId":"EG001","numAffected":6,"numAtRisk":70}]},{"term":"Acute sinusitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13},{"groupId":"EG001","numAffected":0,"numAtRisk":70}]},{"term":"Ear infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13},{"groupId":"EG001","numAffected":5,"numAtRisk":70}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13},{"groupId":"EG001","numAffected":1,"numAtRisk":70}]},{"term":"Viral upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":13},{"groupId":"EG001","numAffected":4,"numAtRisk":70}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":13},{"groupId":"EG001","numAffected":25,"numAtRisk":70}]},{"term":"Oropharyngeal pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13},{"groupId":"EG001","numAffected":6,"numAtRisk":70}]},{"term":"Sputum increased","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13},{"groupId":"EG001","numAffected":3,"numAtRisk":70}]},{"term":"Nasal congestion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":13},{"groupId":"EG001","numAffected":10,"numAtRisk":70}]},{"term":"Productive cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":13},{"groupId":"EG001","numAffected":6,"numAtRisk":70}]},{"term":"Rhinorrhoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":13},{"groupId":"EG001","numAffected":7,"numAtRisk":70}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13},{"groupId":"EG001","numAffected":13,"numAtRisk":70}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":13},{"groupId":"EG001","numAffected":6,"numAtRisk":70}]},{"term":"Activated partial thromboplastin time prolonged","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13},{"groupId":"EG001","numAffected":0,"numAtRisk":70}]},{"term":"International normalised ratio increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13},{"groupId":"EG001","numAffected":0,"numAtRisk":70}]},{"term":"Prothrombin time prolonged","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13},{"groupId":"EG001","numAffected":0,"numAtRisk":70}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13},{"groupId":"EG001","numAffected":2,"numAtRisk":70}]},{"term":"Neck pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13},{"groupId":"EG001","numAffected":1,"numAtRisk":70}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13},{"groupId":"EG001","numAffected":2,"numAtRisk":70}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":13},{"groupId":"EG001","numAffected":6,"numAtRisk":70}]},{"term":"Abnormal behaviour","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13},{"groupId":"EG001","numAffected":0,"numAtRisk":70}]},{"term":"Rash erythematous","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13},{"groupId":"EG001","numAffected":0,"numAtRisk":70}]},{"term":"Pallor","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13},{"groupId":"EG001","numAffected":0,"numAtRisk":70}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true},"pointOfContact":{"title":"Medical Monitor","organization":"Vertex Pharmaceuticals Incorporated","email":"medicalinfo@vrtx.com","phone":"617-341-6777"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2017-07-19","uploadDate":"2019-09-29T13:55","filename":"Prot_000.pdf","size":2351518},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2018-06-22","uploadDate":"2019-09-29T13:58","filename":"SAP_001.pdf","size":1404976}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-04-09"},"conditionBrowseModule":{"meshes":[{"id":"D003550","term":"Cystic Fibrosis"},{"id":"D005355","term":"Fibrosis"}],"ancestors":[{"id":"D010335","term":"Pathologic Processes"},{"id":"D010182","term":"Pancreatic Diseases"},{"id":"D004066","term":"Digestive System Diseases"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"},{"id":"D030342","term":"Genetic Diseases, Inborn"},{"id":"D007232","term":"Infant, Newborn, Diseases"}],"browseLeaves":[{"id":"M8485","name":"Fibrosis","asFound":"Fibrosis","relevance":"HIGH"},{"id":"M6755","name":"Cystic Fibrosis","asFound":"Cystic Fibrosis","relevance":"HIGH"},{"id":"M13102","name":"Pancreatic Diseases","relevance":"LOW"},{"id":"M8883","name":"Gastrointestinal Diseases","relevance":"LOW"},{"id":"M7255","name":"Digestive System Diseases","relevance":"LOW"},{"id":"M11168","name":"Lung Diseases","relevance":"LOW"},{"id":"M14977","name":"Respiratory Tract Diseases","relevance":"LOW"},{"id":"M23686","name":"Genetic Diseases, Inborn","relevance":"LOW"},{"id":"M10276","name":"Infant, Newborn, Diseases","relevance":"LOW"},{"id":"T1710","name":"Cystic Fibrosis","asFound":"Cystic Fibrosis","relevance":"HIGH"}],"browseBranches":[{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC06","name":"Digestive System Diseases"},{"abbrev":"BC08","name":"Respiratory Tract (Lung and Bronchial) Diseases"},{"abbrev":"BC16","name":"Diseases and Abnormalities at or Before Birth"},{"abbrev":"Rare","name":"Rare Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C545203","term":"Ivacaftor"}],"ancestors":[{"id":"D065101","term":"Chloride Channel Agonists"},{"id":"D049990","term":"Membrane Transport Modulators"},{"id":"D045504","term":"Molecular Mechanisms of Pharmacological Action"}],"browseLeaves":[{"id":"M250281","name":"Ivacaftor","asFound":"Dextrose","relevance":"HIGH"}],"browseBranches":[{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":true}
